No abstract available.
Drug Therapy* ; Lung Neoplasms* ; Lung*

No abstract available.
Drug Therapy* ; Lung Neoplasms* ; Lung*

No abstract available.
Drug Therapy* ; Humans ; Lung Neoplasms* ; Lung*

Humans ; Immunotherapy ; Lung ; Lung Neoplasms/drug therapy*

Pathological diagnosis of lung cancer keep updating and developing, in order to meet the clinical needs in the era of precision medicine. It mainly involves the advances of histological subtype classification, molecular testing for targeted therapy, biomarkers detection for immunotherapy and the pathological evaluation for neoadjuvant therapy. Nowadays, pathological diagnosis of lung cancer present a multidisciplinary model including clinical medicine, radiology and pathology. It is gradually moving towards standardization with expection to provide better guidance for clinical treatment and prognosis.
Humans ; Lung Neoplasms/drug therapy* ; Prognosis ; Immunotherapy

Primary pulmonary involvement of Hodgkin's disease is unusual, and can be distinguished from nodal Hodgkin's disease involving the lung secondarily. We report a case of with primary pulmonary manifestation of Hodgkin's disease in young woman who survived 2 years after diagnosis with literature reviews. She had unilateral cavitating lung lesions. After pathological examination, we diagnosed as primary pulmonary Hodgkin's disease, mixed cellularity type and treated with conventional chemotherapy and adjuvant radiation.
Diagnosis ; Drug Therapy ; Female ; Hodgkin Disease* ; Humans ; Lung ; Lung Neoplasms

Intramedullary metastatic tumor comprise about 0.9 to 5% among the spinal metastatic tumors. Authors presented a rare case of intramedullary metastatic spinal cord tumor treated with operative total removal followed by radiation therapy and chemotherapy.
Drug Therapy ; Lung Neoplasms ; Spinal Cord Neoplasms* ; Spinal Cord*

PURPOSE: To determine the therapeutic effect and toxicities of cisplatin and vinorelbine combination chemotherapy in patients with inoperable non-small-cell lung cancer. MATERIALS AND METHODS: Between Jan 1998 and Dec 1999, 28 patients with inoperable non- small-cell lung cancer were treated with cisplatin and vinorelbine combination chemotherapy as induction treatment. A combination of vinorelbine 25 mg/m2 day 1,8 and cisplatin 60 mg/m2 day 1 were given and repeated every 3 weeks. Then we assessed response and toxicity according to WHO grades. RESULTS: According to response criteria, there were 1 complete response, 12 partial response (42.9%), 12 stable disease (42.9%), and 3 progression (10.7%). The median survival was 12 months. According to toxicity grades, 24 grade 3 myelosuppression (24.7%), 12 grade 4 myelo suppression (10.7%), 6 grade 3 and 4 constipation (6.1%), and mild 7 (7.2%) thrombophlebitis were experienced in evaluable 97 cycles. There was no other clinically severe toxicity. CONCLUSION: These results suggest that combination chemotherapy with cisplatin and vinorelbine in patients with inoperable non-small-cell lung cancer was effective and safe.
Cisplatin* ; Constipation ; Drug Therapy ; Drug Therapy, Combination* ; Humans ; Lung Neoplasms* ; Lung* ; Thrombophlebitis

Immune escape mechanisms in non-small cell lung cancer (NSCLC) can disrupt every step of the anti-cancer immune response. In recent years, an increased understanding of the specific mechanisms fueling immune escape has allowed for the development of numerous immunotherapeutic treatments that have been introduced into the clinical practice. The advent of immunotherapy has dramatically changed the current treatment landscape of advanced or metastatic NSCLC because of its durable efficacy and manageable toxicity. In this review, we will first present a brief overview of recent evidence on immune escape mechanisms in NSCLC. We will then discuss the current promising immunotherapeutic strategies in advanced or metastatic NSCLC tumors.
Humans ; Carcinoma, Non-Small-Cell Lung/drug therapy* ; Lung Neoplasms/drug therapy* ; Immunotherapy

Immunotherapy has significantly improved clinical outcomes of non-small cell lung cancer (NSCLC), however, along with the popularization of immunotherapy, immune resistance has become an unavoidable problem. Immunotherapy can induce extensive cellular and molecular alterations in the tumor microenvironment. Considering the mechanisms of immune resistance are not yet fully understood and the efficacy of standard chemotherapy regimens is limited, more effective coping strategies based on resistance mechanisms are urgently needed. In this review, we intend to summarize the known mechanisms of immune resistance and feasible strategies, so as to provide a foundation for clinicians to develop more individualized and precise regimens and finally improve patients' prognosis.
.
Humans ; Carcinoma, Non-Small-Cell Lung/drug therapy* ; Lung Neoplasms/drug therapy* ; Prognosis ; Immunotherapy ; Tumor Microenvironment